Actively Recruiting
Phase 1 Study of JMKX003948 Tablets to Evaluate Safety and Preliminary Effectiveness in Adults with Advanced Renal Cell Carcinoma
Led by Jemincare · Updated on 2024-07-09
80
Participants Needed
1
Research Sites
47 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, pharmacokinetics, and preliminary effectiveness of JMKX003948 tablets in patients with renal cell carcinoma. This open-label Phase 1 study focuses on patients with locally advanced or metastatic clear cell renal cell carcinoma who have measurable lesions and a life expectancy of at least 12 weeks. Participants will receive JMKX003948 tablets in treatment cycles lasting 21 days. The study includes two parts a dose escalation phase to determine the maximum tolerated and administrable dose, followed by a dose expansion phase where subjects receive the recommended dose. Treatment continues until disease progression. During the study, researchers will monitor dose-limiting toxicities, adverse events, and serious adverse events for up to two years. They will also assess objective response rates and duration of response for up to one year. Regular evaluations will include measuring drug levels in plasma and other health assessments. Participants safety and treatment effects will be closely observed throughout the study period.
CONDITIONS
Brief Title
A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma
Research Team
H
Huihui Xiang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here